Ali Satvat Net Worth

The estimated Net Worth of Ali J. Satvat is at least $690 Million dollars as of 3 July 2019. Mr. Satvat owns over 882,353 units of BridgeBio Pharma Inc stock worth over $687,868,273 and over the last 10 years he sold BBIO stock worth over $0. In addition, he makes $1,673,900 as Independent Director at BridgeBio Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Satvat BBIO stock SEC Form 4 insiders trading

Ali has made over 3 trades of the BridgeBio Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 882,353 units of BBIO stock worth $26,382,355 on 3 July 2019.

The largest trade he's ever made was buying 1,103,848 units of BridgeBio Pharma Inc stock on 24 May 2019 worth over $28,622,779. On average, Ali trades about 129,835 units every 16 days since 2014. As of 3 July 2019 he still owns at least 24,575,501 units of BridgeBio Pharma Inc stock.

You can see the complete history of Mr. Satvat stock trades at the bottom of the page.

Ali Satvat biography

Ali J. Satvat serves as Independent Director of the Company. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P., a global private equity and alternative asset management firm, in January 2012 and is a Partner, Co-Head of the Health Care industry team within KKR’s Americas Private Equity platform, and Head of KKR Health Care Strategic Growth. Mr. Satvat is a member of the Investment Committee for KKR’s Americas Private Equity platform and chairs the Investment Committee for KKR Health Care Strategic Growth. Mr. Satvat has served as a member of the boards of directors of Coherus BioSciences, Inc. (Nasdaq: CHRS), a biopharmaceutical company, since May 2014, Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical-stage biopharmaceutical company, since June 2018, PRA Health Sciences, Inc. (Nasdaq: PRAH), a global contract research organization, from September 2013 through April 2018, and numerous privately held companies. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners LLP, a global private equity firm, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, a venture capital subsidiary of Johnson & Johnson, Audax Group, a private equity firm, and The Blackstone Group, a global private equity and alternative asset management firm. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association. Mr. Satvat’s qualifications to serve on our Board of Directors include his expertise in corporate governance, financing, and financial matters and his extensive investment experience in the health care industry.

What is the salary of Ali Satvat?

As the Independent Director of BridgeBio Pharma Inc, the total compensation of Ali Satvat at BridgeBio Pharma Inc is $1,673,900. There are 5 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.

How old is Ali Satvat?

Ali Satvat is 42, he's been the Independent Director of BridgeBio Pharma Inc since 2016. There are 14 older and 7 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.

What's Ali Satvat's mailing address?

Ali's mailing address filed with the SEC is C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK, CA, 94025.

Insiders trading at BridgeBio Pharma Inc

Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.

What does BridgeBio Pharma Inc do?

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Complete history of Mr. Satvat stock trades at Coherus Biosciences Inc, Eidos Therapeutics Inc, and BridgeBio Pharma Inc

BridgeBio Pharma Inc executives and stock owners

BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:

• Neil Kumar,
  Chief Executive Officer, Director
• Charles Homcy,
  Chairman of Pharmaceuticals, Lead Director
• Uma Sinha,
  Chief Scientific Officer
• Brian Stephenson,
  Chief Financial Officer
• Eric Aguiar,
  Independent Director
• Ali Satvat,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Neil Kumar Ph.D.,
  Co-Founder, CEO & Director
• Dr. Brian C. Stephenson C.F.A., Ph.D.,
  CFO, Sec. & Principal Accounting Officer
• James Momtazee,
  Independent Director
• Richard Scheller,
  Chairman of Research and Development, Director
• Dr. Michael Thomas Henderson M.D.,
  Chief Bus. Officer
• Dr. Charles J. Homcy M.D.,
  Chairman of Pharmaceuticals & Lead Director
• Dr. Richard H. Scheller Ph.D.,
  Chairman of R&D and Director
• Dr. Cameron Turtle DPHIL, Ph.D.,
  Chief Strategy Officer
• Randal Scott,
  Independent Director
• Brenton Saunders,
  Independent Director
• Andrew Lo,
  Independent Director
• Ronald Daniels,
  Independent Director
• Michael Henderson,
  Chief Business Officer
• Cameron Turtle,
  Senior Vice President - Portfolio Management and Corporate Development
• Frank Mccormick,
  Chairman of Oncology
• Dr. Frank McCormick Ph.D.,
  Chairman of Oncology
• Grace Rauh,
  VP of Communications
• Dr. Uma Sinha Ph.D.,
  Chief Scientific Officer
• Yi Ching Yau,
  Chief Accounting Officer
• Genetic Disorder L.P.Kkr Ge...,
  
• Management Holdings L.P.Kkr...,
  
• Douglas A. Dachille,
  
• Fred Hassan,
  
• Global Performance Llc Viki...,
  
• Global Investors Lp Viking ...,
  
• Genetic Disorder L.P.Robert...,
  
• Yi Ching Yau,
  Chief Accounting Officer
• Brian M. Stolz,
  Chief Operating Officer
• Hannah Valantine,
  
• Brent L Saunders,
  Director
• Andrea Ellis,
  
• Global Investors Lp Viking ...,
  
• Thomas Trimarchi,
  President and COO